(Q27824815)
Statements
2 references
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase (English)
Tetsuya Kurosu
Kazuhiko Kakihana
Daisuke Mizuchi
Identifiers
2 references
2 references